FDA approves Hospira Topotecan Injection
Hospira, which expects to launch the product by the end of February, said topotecan 4 mg/4 ml is designed to improve caregiver convenience and safety. Hospira US president
WuXi XDC Cayman has signed an agreement to provide Ona Therapeutics with an exclusive global licence to its WuXiTecan-2 payload-linker technology platform for the development of an antibody-drug conjugate (ADC) candidate.
Both studies were 12-week, double-blinded, placebo-controlled clinical trials conducted under the regulatory guidelines of Health Canada. Based on analysis of the data, both the primary and secondary efficacy